CRBP Corbus Pharmaceuticals Holdings Inc.

5.48
-0.12  -2%
Previous Close 5.6
Open 5.58
Price To Book 7.51
Market Cap 354,290,730
Shares 64,651,593
Volume 357,928
Short Ratio
Av. Daily Volume 610,441

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b data due 2020.
Anabasum (Resunab)
Cystic Fibrosis
Phase 2 data due 2020.
Anabasum (Resunab)
Systemic lupus erythematosus (SLE)
Phase 3 data due 2021.
Lenabasum (resunab) - DETERMINE
Dermatomyositis
Phase 3 top-line data due summer 2020.
Resunab - RESOLVE-1
Systemic Sclerosis
Phase 2 open label data presented at EULAR June 14, 2019.
Lenabasum (resunab)
Systemic Sclerosis
Phase 1 trial to be initiated 2H 2019.
CRB-4001
Nonalcoholic steatohepatitis (NASH)